Sign in Subscribe
Diseases

Optimizing Treatment Response in Small Vessel Disease with Vasodilatory Drugs

Strategic Insights

— 2 min read

Research conducted at the University of Oxford has shed light on the effectiveness of vasodilatory drugs in treating small vessel disease, a condition affecting blood flow to the brain. The study, led by Karolina Feakins and colleagues, aimed to identify the most sensitive physiological markers of treatment response to sildenafil, a vasodilating drug, in patients with cerebral small vessel disease (cSVD). The study involved 69 participants who received either sildenafil or a placebo for three weeks, and their responses were measured using various techniques, including transcranial ultrasound (TCD) and magnetic resonance imaging (MRI).

Key Takeaways:

  • The study found that cerebrovascular conductance index (CVCi) and gray matter perfusion on MRI were the most sensitive markers of disease activity and drug response in small vessel disease.
  • CVR indices, specifically CVR-TCD and CVR-GM, were associated with CVR on MRI, indicating their validity in measuring treatment response.
  • The study demonstrated that repeated measures of physiological markers, such as MFV and pulsatility, showed high repeatability, with ICC values ranging from 0.6 to 0.8.
  • The publication is significant as it provides a comprehensive analysis of the OxHARP trial data, offering insights into the optimal markers of treatment response to vasodilatory drugs in small vessel disease.
  • The findings have implications for the development of new treatments and diagnostic tools for cSVD, a condition that affects millions worldwide.

Statistics:

  • 69 participants were involved in the study, with 34 receiving sildenafil and 35 receiving a placebo.
  • The study measured a range of physiological markers, including aortic blood pressure, mean flow velocity (MFV), cerebral pulsatility, cerebrovascular conductance index (CVCi), cerebral perfusion, and corticocephalic blood flow.
  • The ICC values for repeatability ranged from 0.6 to 0.8, indicating high reliability for repeated measures of physiological markers.
  • The study found significant associations between CVR-TCD and CVR-WMH, CVR-GM, and CVR-WM.
  • The publication has been peer-reviewed and is available in the International Journal of Stroke.

Sources:

  • Optimal markers of treatment response to vasodilatory drugs in small vessel disease: An OxHARP trial analysis. International Journal of Stroke, 2025:17474930251360093.
  • International Journal of Stroke can be contacted at: Sage Publications Ltd, 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England.
  • Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, Oxford, UK.
  • Karolina Feakins, Alastair J. S. Webb, Amy Lawson, Catriona Stewart, James Thomas, and Osian Llwyd are the authors of the study.
  • Keywords: Pharmaceuticals, Oxford, Europe, Perfusion, United Kingdom, Impotence Agents, Sildenafil Therapy, Vasodilator Agents, Drugs and Therapies, Health and Medicine, Small-Vessel Disease, Cardiovascular Agents, Genitourinary Tract Agents, Phosphodiesterase Inhibitors, Agents For Pulmonary Hypertension.

Read more